<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646889</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-104</org_study_id>
    <nct_id>NCT04646889</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment</brief_title>
  <official_title>A Phase 1, Pharmacokinetic and Pharmacodynamic Study of AR882 in Adult Volunteers With Various Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics&#xD;
      and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t 1/2) following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLr) following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax following multiple doses of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax following multiple doses of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t 1/2 following multiple doses of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following a single dose of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following multiple doses of AR882 in subjects with renal impairment and normal renal function</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with various degrees of renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR882 Single Dose</intervention_name>
    <description>A single dose of AR882</description>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_label>Renal Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR882 Multiple Dose</intervention_name>
    <description>AR882 taken once daily for 14 days</description>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_label>Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  Males and non-pregnant, non-lactating females&#xD;
&#xD;
          -  Body weight no less than 50 kg&#xD;
&#xD;
          -  sUA greater than or equal to 4.0 mg/dL&#xD;
&#xD;
        Renal Impaired Subjects:&#xD;
&#xD;
        • History of chronic renal impairment (&gt; 6 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  Malignancy within 5 years, except for successfully treated basal or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  History of cardiac abnormalities&#xD;
&#xD;
          -  Active peptic ulcer disease or active liver disease&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
        Renal Impaired Subjects:&#xD;
&#xD;
        • Requires dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Hingorani, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Arthrosi Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director, Clinical Operations</last_name>
    <phone>(949) 393-2676</phone>
    <email>info@arthrosi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arthrosi Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthrosi Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthrosi Investigative Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthrosi Investigative Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

